Edward Catherwood, MD, MS; W. David Fitzpatrick, MD; Mark L. Greenberg, MD; Peter T. Holzberger, MD; David J. Malenka, MD; Barbara R. Gerling, MD; John D. Birkmeyer, MD
Physicians managing patients with nonvalvular atrial fibrillation must consider the risks, benefits, and costs of treatments designed to restore and maintain sinus rhythm compared with those of rate control with antithrombotic prophylaxis.
To compare the cost-effectiveness of cardioversion, with or without antiarrhythmic agents, with that of rate control plus warfarin or aspirin.
A Markov decision-analytic model was designed to simulate long-term health and economic outcomes.
Published literature and hospital accounting information.
Hypothetical cohort of 70-year-old patients with different baseline risks for stroke.
Therapeutic strategies using different combinations of cardioversion alone, cardioversion plus amiodarone or quinidine therapy, and rate control with antithrombotic treatment.
Expected costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness.
Strategies involving cardioversion alone were more effective and less costly than those not involving this option. For patients at high risk for ischemic stroke (5.3% per year), cardioversion alone followed by repeated cardioversion plus amiodarone therapy on relapse was most cost-effective ($9300 per QALY) compared with cardioversion alone followed by warfarin therapy on relapse. This strategy was also preferred for the moderate-risk cohort (3.6% per year), but the benefit was more expensive ($18 900 per QALY). In the lowest-risk cohort (1.6% per year), cardioversion alone followed by aspirin therapy on relapse was optimal.
The choice of optimal strategy and incremental cost-effectiveness was substantially influenced by the baseline risk for stroke, rate of stroke in sinus rhythm, efficacy of warfarin, and costs and utilities for long-term warfarin and amiodarone therapy.
Cardioversion alone should be the initial management strategy for persistent nonvalvular atrial fibrillation. On relapse of arrhythmia, repeated cardioversion plus low-dose amiodarone is cost-effective for patients at moderate to high risk for ischemic stroke.
Catherwood E, Fitzpatrick WD, Greenberg ML, et al. Cost-Effectiveness of Cardioversion and Antiarrhythmic Therapy in Nonvalvular Atrial Fibrillation. Ann Intern Med. 1999;130:625–636. doi: 10.7326/0003-4819-130-8-199904200-00002
Download citation file:
Published: Ann Intern Med. 1999;130(8):625-636.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use